company background image
IDOGEN

Idogen OM:IDOGEN Stock Report

Last Price

kr0.12

Market Cap

kr12.6m

7D

-5.5%

1Y

-62.9%

Updated

11 Jul, 2023

Data

Company Financials +

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

IDOGEN Stock Overview

Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs, and the body’s own cells or tissues in Sweden.

IDOGEN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Idogen AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Idogen
Historical stock prices
Current Share Pricekr0.12
52 Week Highkr0.55
52 Week Lowkr0.015
Beta1.78
1 Month Change-20.20%
3 Month Change41.76%
1 Year Change-62.92%
3 Year Change-98.22%
5 Year Change-99.58%
Change since IPO-99.82%

Recent News & Updates

Recent updates

Shareholder Returns

IDOGENSE BiotechsSE Market
7D-5.5%2.4%0.7%
1Y-62.9%-0.5%1.7%

Return vs Industry: IDOGEN underperformed the Swedish Biotechs industry which returned -6.6% over the past year.

Return vs Market: IDOGEN underperformed the Swedish Market which returned 4.4% over the past year.

Price Volatility

Is IDOGEN's price volatile compared to industry and market?
IDOGEN volatility
IDOGEN Average Weekly Movement194.5%
Biotechs Industry Average Movement9.2%
Market Average Movement6.7%
10% most volatile stocks in SE Market13.1%
10% least volatile stocks in SE Market3.9%

Stable Share Price: IDOGEN is more volatile than 90% of Swedish stocks over the past 3 months, typically moving +/- 87% a day.

Volatility Over Time: IDOGEN's weekly volatility has increased from 95% to 194% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20086Christina Herderhttps://www.idogen.com

Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs, and the body’s own cells or tissues in Sweden. The company’s advanced product candidate is IDO 8 that is designed for patients with severe haemophilia A, who have developed neutralizing antibodies against critical treatment with coagulation factor VIII. It also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection primarily kidney transplantation; and IDO AID for the treatment of autoimmune diseases.

Idogen AB (publ) Fundamentals Summary

How do Idogen's earnings and revenue compare to its market cap?
IDOGEN fundamental statistics
Market Capkr12.58m
Earnings (TTM)-kr44.05m
Revenue (TTM)kr771.00k

16.3x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IDOGEN income statement (TTM)
Revenuekr771.00k
Cost of Revenuekr0
Gross Profitkr771.00k
Other Expenseskr44.82m
Earnings-kr44.05m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

Aug 23, 2023

Earnings per share (EPS)-0.42
Gross Margin100.00%
Net Profit Margin-5,712.97%
Debt/Equity Ratio0%

How did IDOGEN perform over the long term?

See historical performance and comparison